Phase 3 multicenter randomized double-blind group sequential placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents = 6 to

Brief description of study

Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents = 6 to <18 years of age


Clinical Study Identifier: s21-00736
ClinicalTrials.gov Identifier: NCT04649242
Principal Investigator: Vijaya L Atluru.
Other Investigator: Chaula Kharode.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.